Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria

Background: Mutations in the E-cadherin (CDH1) gene are a well documented cause of hereditary diffuse gastric cancer (HDGC). Development of evidence based guidelines for CDH1 screening for HDGC have been complicated by its rarity, variable penetrance, and lack of founder mutations. Methods: Forty th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical genetics Vol. 41; no. 7; pp. 508 - 517
Main Authors: Brooks-Wilson, A R, Kaurah, P, Suriano, G, Leach, S, Senz, J, Grehan, N, Butterfield, Y S N, Jeyes, J, Schinas, J, Bacani, J, Kelsey, M, Ferreira, P, MacGillivray, B, MacLeod, P, Micek, M, Ford, J, Foulkes, W, Australie, K, Greenberg, C, LaPointe, M, Gilpin, C, Nikkel, S, Gilchrist, D, Hughes, R, Jackson, C E, Monaghan, K G, Oliveira, M J, Seruca, R, Gallinger, S, Caldas, C, Huntsman, D
Format: Journal Article
Language:English
Published: England BMJ Publishing Group Ltd 01-07-2004
BMJ Publishing Group LTD
BMJ Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Mutations in the E-cadherin (CDH1) gene are a well documented cause of hereditary diffuse gastric cancer (HDGC). Development of evidence based guidelines for CDH1 screening for HDGC have been complicated by its rarity, variable penetrance, and lack of founder mutations. Methods: Forty three new gastric cancer (GC) families were ascertained from multiple sources. In 42 of these families at least one gastric cancer was pathologically confirmed to be a diffuse gastric cancer (DGC); the other family had intestinal type gastric cancers. Screening of the entire coding region of the CDH1 gene and all intron/exon boundaries was performed by bi-directional sequencing. Results: Novel mutations were found in 13 of the 42 DGC families (31% overall). Twelve of these mutations occur among the 25 families with multiple cases of gastric cancer and with pathologic confirmation of diffuse gastric cancer phenotype in at least one individual under the age of 50 years. The mutations found include small insertions and deletions, splice site mutations, and three non-conservative amino acid substitutions (A298T, W409R, and R732Q). All three missense mutations conferred loss of E-cadherin function in in vitro assays. Multiple cases of breast cancers including pathologically confirmed lobular breast cancers were observed both in mutation positive and negative families. Conclusion: Germline truncating CDH1 mutations are found in 48% of families with multiple cases of gastric cancer and at least one documented case of DGC in an individual under 50 years of age. We recommend that these criteria be used for selecting families for CDH1 mutational analysis.
Bibliography:Correspondence to:
 D Huntsman
 B.C. Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6; dhuntsma@bccancer.bc.ca
 C Caldas
 Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Level 3, Addenbrooke’s Hospital, Cambridge CB2 2XZ, UK; cc234@cam.ac.uk
PMID:15235021
href:jmedgenet-41-508.pdf
ark:/67375/NVC-B9JLW7N8-1
istex:A48D500F4D6BB75B469A1F3AB85D0FFCC3208B3D
local:0410508
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2593
1468-6244
1468-6244
DOI:10.1136/jmg.2004.018275